Generic placeholder image

Current Reviews in Clinical and Experimental Pharmacology

Editor-in-Chief

ISSN (Print): 2772-4328
ISSN (Online): 2772-4336

Meta-Analysis

Intrapleural Thrombolytics for Parapneumonic Effusion: A Network Metaanalysis

Author(s): Kannan Sridharan* and Gowri Sivaramakrishnan

Volume 19, Issue 2, 2024

Published on: 17 October, 2022

Page: [204 - 212] Pages: 9

DOI: 10.2174/2772432817666220928123845

Price: $65

Abstract

Objectives: Intrapleural thrombolytics have been trialed for facilitating pleural fluid drainage in patients with complicated parapneumonic effusion. The present study is a network metaanalysis of randomized clinical trials (RCTs) that have evaluated these thrombolytics.

Methods: Electronic databases (Medline, Cochrane CENTRAL, and Google Scholar) were searched for appropriate RCTs evaluating the therapeutic effect of thrombolytics in patients with complicated parapneumonic effusion. Mortality, the proportion of patients referred for surgical intervention, and serious adverse events were the outcome measures. Random-effects model was used for generating direct and mixed treatment comparison pooled estimates. Grading of the evidence for key comparisons was carried out. Odds ratio with 95% confidence intervals was used to represent the pooled estimates.

Results: Seventy-six studies were retrieved with the search strategy, of which 16 were included. No significant differences were observed in mortality. Compared to normal saline, significantly less proportion of patients was referred for surgical intervention with streptokinase (0.4, 0.2 to 0.8), urokinase (0.4, 0.2 to 0.8), alteplase (0.3, 0.1 to 0.7), and alteplase + DNase (0.2, 0.1 to 0.7). DNase alone increased the risk of referral to surgical intervention (3.4, 1.5 to 7.6). Only streptokinase was observed with an increased risk of serious adverse events compared to normal saline (2.8, 1.1 to 7.1) and alteplase (6.7, 1.1 to 39.9). Moderate quality of evidence was observed for streptokinase with normal saline for the proportion of patients referred for surgical intervention, while either low or very low quality strength was observed for all other comparisons.

Conclusion: Streptokinase, urokinase, alteplase, and alteplase + DNase were observed in patients referred for surgical interventions when used intrapleural in patients with parapneumonic effusion. Alteplase + DNase is likely to outperform others as it was observed with the least risk of patients referred for surgical interventions. Until additional data emerges that changes the pooled estimates, thrombolytics other than streptokinase are preferred due to the increased risk of serious adverse events.

Keywords: Streptokinase, urokinase, alteplase, tissue plasminogen activator, DNase, deoxyribonuclease.

« Previous
Graphical Abstract
[1]
Finch S, Chalmers JD. Parapneumonic effusions: Epidemiology and predictors of pleural infection. Curr Respir Care Rep 2014; 3(2): 52-60.
[http://dx.doi.org/10.1007/s13665-014-0074-4]
[2]
Tsang KY, Leung WS, Chan VL, Lin AW, Chu CM. Complicated parapneumonic effusion and empyema thoracis: Microbiology and predictors of adverse outcomes. Hong Kong Med J 2007; 13(3): 178-86.
[PMID: 17548905]
[3]
Shebl E, Paul M. Parapneumonic Pleural Effusions And Empyema Thoracis. Treasure Island, FL: StatPearls Publishing 2021.
[4]
Davies CWH, Kearney S, Gleeson F, Davies RJO. Predictors of outcome and long-term survival in patients with pleural infection. Am J Respir Crit Care Med 1999; 160(5): 1682-7.
[http://dx.doi.org/10.1164/ajrccm.160.5.9903002] [PMID: 10556140]
[5]
Komissarov AA, Rahman N, Lee YCG, et al. Fibrin turnover and pleural organization: Bench to bedside. Am J Physiol Lung Cell Mol Physiol 2018; 314(5): L757-68.
[http://dx.doi.org/10.1152/ajplung.00501.2017] [PMID: 29345198]
[6]
Tucker T, Idell S. Plasminogen-plasmin system in the pathogenesis and treatment of lung and pleural injury. Semin Thromb Hemost 2013; 39(4): 373-81.
[http://dx.doi.org/10.1055/s-0033-1334486] [PMID: 23504608]
[7]
Idell S. Update on the use of fibrinolysins in pleural disease. Clin Pulm Med 2005; 12(3): 184-90.
[http://dx.doi.org/10.1097/01.cpm.0000163392.76738.84]
[8]
Altmann ES, Crossingham I, Wilson S, Davies HR. Intra-pleural fibrinolytic therapy versus placebo, or a different fibrinolytic agent, in the treatment of adult parapneumonic effusions and empyema. Cochrane Libr 2019; (10): CD002312
[http://dx.doi.org/10.1002/14651858.CD002312.pub4]
[9]
Rouse B, Chaimani A, Li T. Network meta-analysis: An introduction for clinicians. Intern Emerg Med 2017; 12(1): 103-11.
[http://dx.doi.org/10.1007/s11739-016-1583-7] [PMID: 27913917]
[10]
Majid A, Kheir F, Folch A, et al. Concurrent intrapleural instillation of tissue plasminogen activator and DNase for pleural infection - a single-center experience. Ann Am Thorac Soc 2016; 13(9): 1512-8.
[http://dx.doi.org/10.1513/AnnalsATS.201602-127OC] [PMID: 27333122]
[11]
Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: Checklist and explanations. Ann Intern Med 2015; 162(11): 777-84.
[http://dx.doi.org/10.7326/M14-2385] [PMID: 26030634]
[12]
Higgins JPT, Thomas J, Chandler J, et al. Cochrane Handbook for Systematic Reviews of Interventions 2nd Ed Chichester: John Wiley and Sons 2019. Available from: www.training.cochrane.org/handbook
[13]
Sedgwick P, Marston L. How to read a funnel plot in a meta-analysis. BMJ 2015; 351: h4718.
[http://dx.doi.org/10.1136/bmj.h4718] [PMID: 26377337]
[14]
Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21(11): 1539-58.
[http://dx.doi.org/10.1002/sim.1186] [PMID: 12111919]
[15]
Aleman C, Porcel JM, Alegre J, Ruiz E, Bielsa S, Andreu J. Intrapleural fibrinolysis with urokinase versus alteplase in complicated parapneumonic pleural effusions and empyemas: A prospective randomized study. Lung 2015; 193(6): 993-1000.
[16]
Bouros D, Schiza S, Alegre J, et al. Intrapleural streptokinase versus urokinase in the treatment of complicated parapneumonic effusions. Am J Respir Crit Care Med 1997; 155(1): 291-5.
[http://dx.doi.org/10.1164/ajrccm.155.1.9001327] [PMID: 9001327]
[17]
Bouros D, Schiza S, Tzanakis N, Chalkiadakis G, Drositis J, Siafakas N. Intrapleural urokinase versus normal saline in the treatment of complicated parapneumonic effusions and empyema. Am J Respir Crit Care Med 1999; 159(1): 37-42.
[http://dx.doi.org/10.1164/ajrccm.159.1.9803094] [PMID: 9872815]
[18]
Davies RJ, Traill ZC, Gleeson FV. Randomised controlled trial of intrapleural streptokinase in community acquired pleural infection. Thorax 1997; 52(5): 416-21.
[http://dx.doi.org/10.1136/thx.52.5.416] [PMID: 9176531]
[19]
Diacon AH, Theron J, Schuurmans MM, Van de Wal BW, Bolliger CT. Intrapleural streptokinase for empyema and complicated parapneumonic effusions. Am J Respir Crit Care Med 2004; 170(1): 49-53.
[http://dx.doi.org/10.1164/rccm.200312-1740OC] [PMID: 15044206]
[20]
Hanson SJ, Havens PL, Simpson PM, Nugent ML, Wells RG. Intrapleural alteplase decreases parapneumonic effusion volume in children more than saline irrigation. Pediatr Pulmonol 2015; 50(12): 1328-35.
[http://dx.doi.org/10.1002/ppul.23184] [PMID: 25847131]
[21]
Lin JC, Zhang CR, Xu WM, Li M, Cui WL. Effectiveness and safety of intrapleural tissue plasminogen activator in the prevention of pleural thickening and loculated effusions by infective pleurisy. Int J Infect Dis 2011; 15(S1): S104-5.
[http://dx.doi.org/10.1016/S1201-9712(11)60365-2]
[22]
Livingston MH, Mahant S, Connolly B, et al. Effectiveness of intrapleural tissue plasminogen activator and dornase alfa vs. tissue plasminogen activator alone in children with pleural empyema. JAMA Pediatr 2020; 174(4): 332-40.
[http://dx.doi.org/10.1001/jamapediatrics.2019.5863] [PMID: 32011642]
[23]
Maskell NA, Davies CWH, Nunn AJ, et al. U.K. Controlled trial of intrapleural streptokinase for pleural infection. N Engl J Med 2005; 352(9): 865-74.
[http://dx.doi.org/10.1056/NEJMoa042473] [PMID: 15745977]
[24]
Misthos P, Sepsas E, Konstantinou M, Athanassiadi K, Skottis I, Lioulias A. Early use of intrapleural fibrinolytics in the management of postpneumonic empyema. A prospective study. Eur J Cardiothorac Surg 2005; 28(4): 599-603.
[http://dx.doi.org/10.1016/j.ejcts.2005.07.005] [PMID: 16129614]
[25]
Prasad BNBM, Bhattacharyya D, Luthra M, Mathur AD. Management of empyema thoracis with pleural pigtail drainage and intrapleural thrombolytic therapy. Am J Respir Crit Care Med 2009; 179: A4486.
[26]
Rahman NM, Maskell NA, West A, et al. Intrapleural use of tissue plasminogen activator and DNase in pleural infection. N Engl J Med 2011; 365(6): 518-26.
[http://dx.doi.org/10.1056/NEJMoa1012740] [PMID: 21830966]
[27]
Singh M, Mathew JL, Chandra S, Katariya S, Kumar L. Randomized controlled trial of intrapleural streptokinase in empyema thoracis in children. Acta Paediatr 2004; 93(11): 1443-5.
[http://dx.doi.org/10.1111/j.1651-2227.2004.tb02626.x] [PMID: 15513569]
[28]
Thommi G, Shehan JC, Robison KL, Christensen M, Backemeyer LA, McLeay MT. A double blind randomized cross over trial comparing rate of decortication and efficacy of intrapleural instillation of alteplase vs. placebo in patients with empyemas and complicated parapneumonic effusions. Respir Med 2012; 106(5): 716-23.
[http://dx.doi.org/10.1016/j.rmed.2012.02.005] [PMID: 22398159]
[29]
Thomson AH, Hull J, Kumar MR, Wallis C, Balfour Lynn IM. Randomised trial of intrapleural urokinase in the treatment of childhood empyema. Thorax 2002; 57(4): 343-7.
[http://dx.doi.org/10.1136/thorax.57.4.343] [PMID: 11923554]
[30]
Tuncozgur B, Ustunsoy H, Sivrikoz MC, et al. Intrapleural urokinase in the management of parapneumonic empyema: A randomised controlled trial. Int J Clin Pract 2001; 55(10): 658-60.
[PMID: 11777287]
[31]
Shen KR, Bribriesco A, Crabtree T, et al. The American association for thoracic surgery consensus guidelines for the management of empyema. J Thorac Cardiovasc Surg 2017; 153(6): e129-46.
[http://dx.doi.org/10.1016/j.jtcvs.2017.01.030] [PMID: 28274565]
[32]
Redden MD, Chin TY, van Driel ML. Surgical versus non-surgical management for pleural empyema. Cochrane Libr 2017; 2017(3)CD010651
[http://dx.doi.org/10.1002/14651858.CD010651.pub2] [PMID: 28304084]
[33]
Laisaar T, Pullerits T. Effect of intrapleural streptokinase administration on antistreptokinase antibody level in patients with loculated pleural effusions. Chest 2003; 123(2): 432-5.
[http://dx.doi.org/10.1378/chest.123.2.432] [PMID: 12576362]
[34]
Chai F, Kuan Y. Massive hemothorax following administration of intrapleural streptokinase. Ann Thorac Med 2011; 6(3): 149-51.
[http://dx.doi.org/10.4103/1817-1737.82451] [PMID: 21760848]
[35]
Nie W, Liu Y, Ye J, et al. Efficacy of intrapleural instillation of fibrinolytics for treating pleural empyema and parapneumonic effusion: A meta-analysis of randomized control trials. Clin Respir J 2014; 8(3): 281-91.
[http://dx.doi.org/10.1111/crj.12068] [PMID: 24428897]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy